Polysaccharide vaccines against diseases caused by Neisseria meningitidis serogroups A and C meningococci are now licensed in the United States. They are prepared as monovalent and as bivalent antigens. This statement summarizes available information on these antigens and offers guidance regarding their role in the control of epidemics of meningococcal disease in the civilian population of the U.S.
Learn more about subscription options.
Register Now for a free account.
Meningococcal Polysaccharide Vaccines. Ann Intern Med. 1976;84:179–180. doi: 10.7326/0003-4819-84-2-179
Download citation file:
Published: Ann Intern Med. 1976;84(2):179-180.
Infectious Disease, Prevention/Screening, Vaccines/Immunization.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only